FOLFOXIRI-Bev as first-line treatment in patients with metastatic colorectal cancer: a systematic review of RCT

被引：0
|
作者：
Luih, B. Stephanie [1 ]
Samudra, E. [1 ]
Suwongto, G. Sonia [1 ]
Glory, H. [1 ]
Colfoort, K. [1 ]
Wirajaya, P. [1 ]
Kurniawan, A. [1 ]
机构：
[1] Pelita Harapan Univ, Sch Med Pelita Harapan, Banten, Indonesia
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.07.588
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO42-1
引用
收藏
页码：S1349 / S1350
页数：2
相关论文
共 50 条
  • [41] Role of cetuximab in first-line treatment of metastatic colorectal cancer
    Miguel Jhonatan Sotelo
    Beatriz García-Paredes
    Carlos Aguado
    Javier Sastre
    Eduardo Díaz-Rubio
    World Journal of Gastroenterology, 2014, (15) : 4208 - 4219
  • [42] Role of cetuximab in first-line treatment of metastatic colorectal cancer
    Sotelo, Miguel Jhonatan
    Garcia-Paredes, Beatriz
    Aguado, Carlos
    Sastre, Javier
    Diaz-Rubio, Eduardo
    WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (15) : 4208 - 4219
  • [43] Recent advances in first-line treatment of metastatic colorectal cancer
    Fakih, Marwan
    COLORECTAL CANCER, 2012, 1 (02) : 111 - 114
  • [44] First-line treatment in metastatic colorectal cancer: Important or crucial?
    Malka, David
    Rotolo, Federico
    Boige, Valerie
    EUROPEAN JOURNAL OF CANCER, 2017, 84 : 363 - 366
  • [45] Update analysis of phase Ib study of FOLFOXIRI plus ramucirumab as first-line therapy for patients with metastatic colorectal cancer
    Yamada, T.
    Kito, Y.
    Satake, H.
    Taniguchi, H.
    Horie, Y.
    Esaki, T.
    Denda, T.
    Mori, K.
    Yamazaki, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [46] FOLFOXIRI with or without bevacizumab as first-line treatment for unresectable liver-only metastatic colorectal cancer patients with RAS mutation-type.
    Deng, Yanhong
    Hu, Huabin
    Liu, Guanjian
    Cai, Yue
    Zhang, Jianwei
    Huang, Meijin
    Wang, Lei
    Ping, Lan
    Wang, Jianping
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [47] Efficacy of Bevacizumab in the First-Line Treatment of Patients with RAS Mutations Metastatic Colorectal Cancer: a Systematic Review and Network Meta-Analysis
    Zhou, Mingyi
    Yu, Ping
    Qu, Jinglei
    Chen, Ying
    Zhou, Yang
    Fu, Lingyu
    Zhang, Jingdong
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2016, 40 (1-2) : 361 - 369
  • [48] The safety and efficacy of FOLFOXIRI plus molecular target therapy as a first-line treatment for metastatic colorectal cancer: A multicentre retrospective study
    Ogata, T.
    Satake, H.
    Ogata, M.
    Hatachi, Y.
    Hamada, M.
    Yasui, H.
    ANNALS OF ONCOLOGY, 2018, 29
  • [49] Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer
    Xuetong Rong
    Haiyi Liu
    Hongmei Yu
    Jian Zhao
    Jie Wang
    Yusheng Wang
    Investigational New Drugs, 2022, 40 : 340 - 348
  • [50] Reply: Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
    J Feliu
    J Barriuso
    British Journal of Cancer, 2011, 104 : 226 - 226
12345